Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2

Li Wang; Yujuan Zhang; Kangdong Liu; Hanyong Chen; Ran Yang; Xiaoli Ma; Hong-Gyum Kim; Ann M. Bode; Dong Joon Kim; Zigang Dong

doi:10.18632/oncotarget.24409

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2

Li Wang, Yujuan Zhang, Kangdong Liu, Hanyong Chen, Ran Yang, Xiaoli Ma, Hong-Gyum Kim, Ann M. Bode, Dong Joon Kim _ and Zigang Dong

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:34200-34212. https://doi.org/10.18632/oncotarget.24409

Metrics: PDF 1614 views | HTML 2264 views | ?

Abstract

Li Wang1, Yujuan Zhang1, Kangdong Liu1,2,3,4, Hanyong Chen5, Ran Yang1, Xiaoli Ma1,2, Hong-Gyum Kim1, Ann M. Bode5, Dong Joon Kim1 and Zigang Dong1,5

1China–US (Henan) Hormel Cancer Institute, Henan, China

2The Pathophysiology Department, The School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China

3The Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou, Henan, China

4The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou, China

5The Hormel Institute, University of Minnesota, Austin, MN, USA

Correspondence to:

Dong Joon Kim, email: [email protected]

Zigang Dong, email: [email protected]

Keywords: carnosol; RSK2; gastric cancer; patient-derived tumor xenograft

Received: September 22, 2017 Accepted: January 09, 2018 Epub: February 06, 2018 Published: September 28, 2018

ABSTRACT

Carnosol is a phenolic diterpene that is isolated from rosemary, sage, and oregano. It has been reported to possess anti-oxidant, anti-inflammatory, and anti-cancer properties. However, the molecular mechanism of carnosol’s activity against gastric cancer has not been investigated. Herein, we report that carnosol is an RSK2 inhibitor that attenuates gastric cancer growth. Carnosol reduced anchorage-dependent and -independent gastric cancer growth by inhibiting the RSKs-CREB signaling pathway. The results of in vitro screening and cell-based assays indicated that carnosol represses RSK2 activity and its downstream signaling. Carnosol increased the G2/M phase and decreased S phase cell cycle and also induced apoptosis through the activation of caspases 9 and 7 and inhibition of Bcl-xL expression. Notably, oral administration of carnosol suppressed patient-derived gastric tumor growth in an in vivo mouse model. Our findings suggest that carnosol is an RSK2 inhibitor that could be useful for treating gastric cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24409

Publication Alerts

Research Papers:

Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2

Abstract